Zydus Lifesciences introduces new drug in US markets

According to IQVIA MAT data, Mirabegron extended-release tablets (USP 25mg and 50mg) had yearly sales of USD 2.42 billion in the United States.

Related Keywords

Ahmedabad , Gujarat , India , United States , Zydus Lifesciences , Punit Patel , Cadila Healthcare , Overactive Bladder , Ahmedabad Special Economic Zone , Zydus Americas , Lifesciences Limited , Cadila Healthcare Limited ,